Potiga Effective for Treating Seizures, FDA Advisory Panel Says

A Food and Drug Administration advisory committee Aug. 11 voted unanimously that Potiga (ezogabine) is effective as adjunctive treatment for adults with partial-onset seizures.

The Peripheral and Central Nervous System Drugs Advisory Committee voted 13 to 0 that clinical trials have provided substantial evidence of the effectiveness of Potiga as adjunctive treatment for adults with partial-onset seizures, an FDA spokeswoman told BNA Aug. 12. Potiga was co-developed by Valeant Pharmaceuticals International and GlaxoSmithKline.

FDA specifically asked the committee to comment on risks associated with urinary retention. In clinical trials, urinary retention occurred at a rate of 0.9 percent in patients ...